临床一线抗病毒药物对慢性乙型肝炎治疗结局的影响  

Effect of clinical first-line Antiviral Agents on outcome of chronic hepatitis B treatment

作　　者：赵龙凤[1] 王艳[1] 

机构地区：[1]山西医科大学第一医院感染病科,太原030001

出　　处：《中华肝脏病杂志》2017年第7期485-489,共5页Chinese Journal of Hepatology

摘　　要：慢性乙型肝炎是一种进展性疾病，治疗不及时就有可能发展为肝硬化、肝癌甚至肝功能衰竭。抗病毒治疗是延缓慢性乙型肝炎的疾病进展的重要手段，通过长期抑制HBVDNA复制，可减轻肝细胞炎性坏死及肝纤维化，延缓和减少肝功能衰竭、肝硬化失代偿、肝细胞癌及其他并发症的发生，从而改善生活质量和延长生存时间。本文从目前全球正在使用的恩替卡韦、替诺福韦酯等一线抗病毒药物的临床研究数据出发，阐述了抗病毒治疗对于慢性乙型肝炎患者治疗结局的影响。Chronic hepatitis B is a progressive disease that can develop into cirrhosis, liver cancer or even liver failure if it is not treated in time. Antiviral therapy is an important means to delay the progression of chronic hepatitis B disease, through long-term inhibition of HBV DNA replication can reduce liver cell inflammation and necrosis, fibrosis, delaying and reducing liver failure, cirrhosis, HCC and other complications, which can improve the life quality and prolong survival time. Based on the data of hepatitis B first-line Antiviral Agents such as entecavir and tenofovir And so on. being used worldwide, this paper expounds the influence of antiviral therapy on the outcome of chronic hepatitis B treatment.

关 键 词：肝炎 乙型 慢性 干扰素类 治疗 结局 抗病毒药 核苷(酸) 类似物 

分 类 号：R512.62[医药卫生—内科学]